Subsequent analyses of HELQ and XAB2 expressions in ascites tumor cells and clinical data showed statistically significant increased distribution of platinum resistance in patients with high-expression of HELQ (P < 0.001) and XAB2 (P = 0.006). The gene discussed is HELQ; the disease is neoplasm.